Many components of abortion care in early pregnancy can safely be provided on an
outpatient basis by mid-level providers or by pregnant people themselves. Yet, some states …

Importance Screening for medication abortion eligibility typically includes ultrasonography
or pelvic examination. To reduce physical contact during the COVID-19 pandemic, many …

Abstract Objectives: In 2000, the United States' Food and Drug Administration (FDA)
approved mifepristone for medication abortion. In this article, we explore how the Risk …

Few obstetrician–gynecologists (ob-gyns) provide abortion care, resulting in abortion being
separated from other reproductive health care. This segregation of services disrupts the ob …

Importance Before 2021, the US Food and Drug Administration required mifepristone to be
dispensed in person, limiting access to medication abortion. Objective To estimate the …

Objectives Following the 2017 introduction of mifepristone in Canada and both ensuing
regulatory changes and increased demand for medication abortion care, Planned …

Context Early pregnancy loss (EPL) affects 1 million patients in the United States (US)
annually, but integration of mifepristone into EPL care may be complicated by regulatory …

Background Early pregnancy loss, also referred to as miscarriage, is common, affecting
approximately 1 million people in the United States annually. Early pregnancy loss can be …

Objective To assess barriers to and facilitators of abortion provision among abortion-trained
primary care providers. Study Design We conducted 21 qualitative in-depth interviews with …

Abstract Objectives The ExPAND Mifepristone (ExPAND) learning collaborative aims to
support primary care providers in overcoming logistical barriers to mifepristone provision …